AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20589313 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 2
Study 20589313 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779
Number of subjects: 2
Study 20589313 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779 and desmopressin combination
Number of subjects: 2
Study 17386345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g) and Vitamin E (400 IU)
Number of subjects: 30
Study 17386345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15482066 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming paradigm with tightly controlled attention to ensure irrelevant stimuli were not attended.
Number of subjects: 0
Study 11506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ET)
Number of subjects: 65
Study 11506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength promotion exercise (SP)
Number of subjects: 65
Study 11506213 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 65
Study 11506213 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (T3)
Number of subjects: 65
Study 9693397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.02 mg ethinyl estradiol and 0.15 mg desogestrel (preparation A)
Number of subjects: 29
Study 9693397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.03 mg ethinyl estradiol and 2.00 mg dienogest (preparation B)
Number of subjects: 29
Study 7840712 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 50
Study 3277153 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of therapy with cefaclor (40 mg/kg/day)
Number of subjects: 175
Study 3277153 — intervention group
Group type: COMPARATOR
Intervention: 10 days of therapy with cefaclor (40 mg/kg/day)
Number of subjects: 175
Study 3277153 — intervention group
Group type: COMPARATOR
Intervention: 5 days vs 10 days of therapy
Number of subjects: 175
Study 30391333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg/day
Number of subjects: 165
Study 30391333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg/day
Number of subjects: 165
Study 30391333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 27495072 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided split injection technique for rectus sheath block (RSB group, n=20)
Number of subjects: 40
Study 27495072 — intervention group
Group type: COMPARATOR
Intervention: No block (control group, n=20)
Number of subjects: 40
Study 27495072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25022248 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ASD
Number of subjects: 31
Study 25022248 — intervention group
Group type: COMPARATOR
Intervention: Typically-developing (TD) children
Number of subjects: 31
Study 21828175 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-stigma intervention
Number of subjects: 616
Study 21828175 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 616
Study 20650049 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation: escitalopram (10 mg tablet) manufactured by Apsen Farmacêutica S.A.
Number of subjects: 0
Study 20650049 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation: escitalopram (Lexapro; 10 mg tablet) from Lundbeck Brasil Ltda
Number of subjects: 0
Study 18605603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP) (Straumann Bone Ceramic)
Number of subjects: 12
Study 18605603 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone matrix (ABBM) (Bio‐Oss)
Number of subjects: 12
Study 16088856 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for women with CMI
Number of subjects: 121
Study 16088856 — intervention group
Group type: COMPARATOR
Intervention: Group therapy for women without CMI
Number of subjects: 121
Study 12366895 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian patients
Number of subjects: 0
Study 12366895 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American patients
Number of subjects: 0
Study 12366895 — intervention group
Group type: COMPARATOR
Intervention: Immigrants
Number of subjects: 0
Study 12366895 — intervention group
Group type: COMPARATOR
Intervention: Patients requiring a translator
Number of subjects: 0
Study 10655814 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum advice supplied by a video film, explanatory leaflet, and open discussion.
Number of subjects: 601
Study 9005422 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid imaging with 99m Tc‐MIBI
Number of subjects: 13
Study 9005422 — intervention group
Group type: COMPARATOR
Intervention: High‐resolution ultrasonography
Number of subjects: 13
Study 1875542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine and buprenorphine 0.2 mg (48 ml.hr‐1)
Number of subjects: 32
Study 1875542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% mepivacaine and buprenorphine 0.4 mg (48 ml.hr‐1)
Number of subjects: 32
Study 1875542 — intervention group
Group type: COMPARATOR
Intervention: saline and buprenorphine 0.2 mg (48 ml.hr‐1)
Number of subjects: 32
Study 1875542 — intervention group
Group type: COMPARATOR
Intervention: saline and buprenorphine 0.4 mg (48 ml.hr‐1)
Number of subjects: 32
Study 6981522 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 g erythromycin ethyl succinate granules twice daily orally for 10 days)
Number of subjects: 22
Study 6981522 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin + Bromhexine
Number of subjects: 22
Study 6981522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31581947 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT intervention
Number of subjects: 439
Study 28004415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL)
Number of subjects: 2323
Study 28004415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol : high-density lipoprotein ratio
Number of subjects: 2323
Study 28004415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol and low-density lipoprotein (LDL)
Number of subjects: 2323
Study 28004415 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 2323
Study 25607117 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to jazz music (BPM <100) for 30 min in the PACU (n=28)
Number of subjects: 56
Study 25607117 — intervention group
Group type: COMPARATOR
Intervention: Wearing noise-canceling headphones for 30 min in the PACU (n=28)
Number of subjects: 56
Study 24727078 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (ICBT)
Number of subjects: 182
Study 24727078 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 182
Study 24727078 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) combined (ICBT and GCBT)
Number of subjects: 182
Study 21901395 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based dose-dense sequential chemotherapy
Number of subjects: 595
Study 21901395 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant anthracycline-based dose-dense sequential chemotherapy with paclitaxel
Number of subjects: 595
Study 20813593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone 500 mg IV
Number of subjects: 0
Study 20813593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone 1000 mg IV
Number of subjects: 0
Study 20813593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone 2000 mg IV
Number of subjects: 0
Study 20813593 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazedone
Number of subjects: 0
Study 17985009 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced secondary prevention program
Number of subjects: 2643
Study 17985009 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2643
Study 15923569 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI) 250 mg/d
Number of subjects: 368
Study 15923569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 15923569 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyaminoimidazole (CAI)
Number of subjects: 368
Study 11970938 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured letters
Number of subjects: 32
Study 11970938 — intervention group
Group type: COMPARATOR
Intervention: Conventional letters
Number of subjects: 32
Study 9809381 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (15 g/d)
Number of subjects: 20
Study 9809381 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (2 g/d)
Number of subjects: 20
Study 9809381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7654159 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased perceived responsibility
Number of subjects: 30
Study 7654159 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased perceived responsibility
Number of subjects: 30
Study 2439782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 to 20 mg)
Number of subjects: 94
Study 2439782 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 94
Study 2439782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 94
Study 2439782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 94
Study 29178659 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) intervention for 16 weeks
Number of subjects: 110
Study 29178659 — intervention group
Group type: COMPARATOR
Intervention: Migraine Education (ME) control for 16 weeks
Number of subjects: 110
Study 29178659 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) intervention
Number of subjects: 110
Study 29178659 — intervention group
Group type: COMPARATOR
Intervention: Migraine Education (ME) control
Number of subjects: 110
Study 27999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Craigslist
Number of subjects: 2149
Study 27999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Word of mouth
Number of subjects: 2149
Study 27999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 2149
Study 27999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyers or postcards
Number of subjects: 2149
Study 27999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal contact
Number of subjects: 2149
Study 27999280 — intervention group
Group type: COMPARATOR
Intervention: Newspaper ads in California
Number of subjects: 2149
Study 27999280 — intervention group
Group type: COMPARATOR
Intervention: Staff in-person recruiting in North Carolina
Number of subjects: 2149
Study 24944041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg/day for 7 days) with PF-04449913 (200 mg single dose on day 4)
Number of subjects: 0
Study 24944041 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal with PF-04449913 (200 mg single dose)
Number of subjects: 0
Study 24944041 — intervention group
Group type: COMPARATOR
Intervention: PF-04449913 alone (200 mg single dose)
Number of subjects: 0
Study 22348605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol 75 mg t.d.s. for 48 h
Number of subjects: 38
Study 22348605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg t.d.s. for 48 h
Number of subjects: 38
Study 22348605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 20122630 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group G2 (dissemination of SEPAR guidelines)
Number of subjects: 1481
Study 20122630 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group G3 (dissemination of SEPAR guidelines and distribution of Koko Peak Pro)
Number of subjects: 1481
Study 20122630 — intervention group
Group type: COMPARATOR
Intervention: Control group G1 (usual clinical practice)
Number of subjects: 1481
Study 20122630 — intervention group
Group type: COMPARATOR
Intervention: Control group G1 vs Training group G3
Number of subjects: 1481
Study 18718471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 74
Study 18718471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 18491553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative face‐based surface registration
Number of subjects: 11
Study 18491553 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature PBR
Number of subjects: 11
Study 18491553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical vessel‐contour registration
Number of subjects: 11
Study 18491553 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained geometric/intensity registration
Number of subjects: 11
Study 18491553 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained geometric/intensity registration
Number of subjects: 11
Study 15039691 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine with epigastric pressure
Number of subjects: 65
Study 15039691 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine
Number of subjects: 65
Study 15039691 — intervention group
Group type: COMPARATOR
Intervention: Leg raise
Number of subjects: 65
Study 15039691 — intervention group
Group type: COMPARATOR
Intervention: Semirecumbent position
Number of subjects: 65
Study 15039691 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 65
Study 11505114 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpyloric enteral feeds
Number of subjects: 33
Study 11505114 — intervention group
Group type: COMPARATOR
Intervention: Gastric enteral feeds
Number of subjects: 33
Study 11505114 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal regurgitation
Number of subjects: 33
Study 9106787 — intervention group
Group type: COMPARATOR
Intervention: 20% fat emulsion formulation
Number of subjects: 50
Study 9106787 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% formulation enriched 10-fold with phospholipids
Number of subjects: 50
Study 8149250 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (7000 cGy in 47 days or 7500 cGy in 54 days)
Number of subjects: 372
Study 3520619 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antibacterial agents (variety of local antibacterials)
Number of subjects: 124
Study 3520619 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent povidone-iodine (50 percent Betadine) solution
Number of subjects: 124
Study 31584922 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth appointment for cast removal (group B)
Number of subjects: 52
Study 31584922 — intervention group
Group type: COMPARATOR
Intervention: In-person cast removal at institution (group A)
Number of subjects: 52
Study 30230266 — intervention group
Group type: COMPARATOR
Intervention: 150 M PLX-PAD
Number of subjects: 20
Study 30230266 — intervention group
Group type: COMPARATOR
Intervention: Low-dose treatment (150 M)
Number of subjects: 20
Study 30230266 — intervention group
Group type: COMPARATOR
Intervention: High-dose treatment (300 M)
Number of subjects: 20
Study 26952309 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 2331
Study 26952309 — intervention group
Group type: COMPARATOR
Intervention: Formoterol
Number of subjects: 2331
Study 24462483 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg zinc sulfate for 14 days)
Number of subjects: 234
Study 24462483 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (single dose)
Number of subjects: 234
Study 24462483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 23147875 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy every 2 hours (CPAP 2 hrs)
Number of subjects: 108
Study 23147875 — intervention group
Group type: COMPARATOR
Intervention: Incentive spirometry (IS) therapy
Number of subjects: 108
Study 23147875 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy every 4 hours (CPAP 4 hrs)
Number of subjects: 108
Study 23147875 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 108
Study 23147875 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (CPAP 2 hrs, CPAP 4 hrs, IS)
Number of subjects: 108
Study 19280112 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily for 2 weeks
Number of subjects: 130
Study 19280112 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 10 mg twice daily for 2 weeks
Number of subjects: 130
Study 19280112 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 10 mg twice daily for a third 2-week period
Number of subjects: 130
Study 17192288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/d
Number of subjects: 3240
Study 17192288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/d
Number of subjects: 3240
Study 17192288 — intervention group
Group type: COMPARATOR
Intervention: CEE/MPA (0.625 + 2.5 mg/d)
Number of subjects: 3240
Study 15365707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 100 mg/day
Number of subjects: 35
Study 15365707 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine 300 mg/day
Number of subjects: 35
Study 15365707 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day (4-week trial)
Number of subjects: 35
Study 11259519 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety equipment present during assessments of risk tolerance
Number of subjects: 151
Study 11259519 — intervention group
Group type: COMPARATOR
Intervention: Safety equipment not present during assessments of risk tolerance
Number of subjects: 151
Study 11259519 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in the presence of safety equipment
Number of subjects: 151
Study 11259519 — intervention group
Group type: COMPARATOR
Intervention: Children in the absence of safety equipment
Number of subjects: 151
Study 9700674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 10 ml
Number of subjects: 48
Study 9700674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (10 ml, 30 ml)
Number of subjects: 48
Study 9700674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin 50 ml
Number of subjects: 48
Study 9700674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 48
Study 9700674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (all doses)
Number of subjects: 48
Study 8305754 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of EMLA cream
Number of subjects: 89
Study 8305754 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration with lignocaine
Number of subjects: 89
Study 2903143 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 2903143 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study 31714323 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 366
Study 31714323 — intervention group
Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 366
Study 30145391 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI‐II)
Number of subjects: 709
Study 30145391 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ‐9)
Number of subjects: 709
Study 30145391 — intervention group
Group type: EXPERIMENTAL
Intervention: General depression factors (BDI‐II and PHQ‐9)
Number of subjects: 709
Study 30145391 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted regression models
Number of subjects: 709
Study 28265816 — intervention group
Group type: EXPERIMENTAL
Intervention: Morinidazole (500 mg twice daily for 14 days)
Number of subjects: 338
Study 28265816 — intervention group
Group type: COMPARATOR
Intervention: Ornidazole (500 mg twice daily for 14 days)
Number of subjects: 338
Study 25540268 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine (2.5‐μg dose, Al(OH)(3)‐adjuvanted, with second and third doses after 3 weeks and 6 months)
Number of subjects: 1964
Study 25540268 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated whole‐virus Vero cell culture‐derived RRV vaccine
Number of subjects: 1964
Study 22957911 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implant-abutment connection (test)
Number of subjects: 92
Study 22957911 — intervention group
Group type: COMPARATOR
Intervention: Platform-matched implant-abutment connection (control)
Number of subjects: 92
Study 20577111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable sutures
Number of subjects: 50
Study 20577111 — intervention group
Group type: COMPARATOR
Intervention: Laser suture lysis
Number of subjects: 50
Study 18315420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline hydroxyapatite (NHA) paste
Number of subjects: 28
Study 18315420 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 28
Study 18315420 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NHA paste and open flap debridement
Number of subjects: 28
Study 16573800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Number of subjects: 0
Study 16573800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 6‐mg/h continuous infusion
Number of subjects: 0
Study 16573800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 7.5‐mg/h continuous infusion
Number of subjects: 0
Study 16573800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 90‐mg intravenous bolus followed by 9‐mg/h continuous infusion
Number of subjects: 0
Study 16573800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12452516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metronidazole and povidone iodine
Number of subjects: 50
Study 12452516 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine alone
Number of subjects: 50
Study 10511022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension
Number of subjects: 25
Study 10511022 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% ophthalmic solution
Number of subjects: 25